ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2023
Guideline-Concordant Antiviral Treatment in Children at High Risk for Influenza Complications.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 21 citations in OpenAlex.
- A noninferiority randomized open-label pilot study of 3- versus 7-day influenza postexposure prophylaxis with oseltamivir in hospitalized children.Scientific reports · 2024Trial
- Antiviral Use Among Children Hospitalized With Laboratory-Confirmed Influenza Illness: A Prospective, Multicenter Surveillance Study.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2025Article
- Changes in Antiviral Prescribing for Children With Influenza in US Emergency Departments.JAMA network open · 2025Article
- Influenza With and Without Oseltamivir Treatment and Neuropsychiatric Events Among Children and Adolescents.JAMA neurology · 2025Article
- Influenza Antivirals: Do We Need More Evidence?Pediatrics · 2025Article
- Factors Associated with Antiviral Drug Use Among Commercially Insured Children at High Risk for Complications of Influenza.The Journal of pediatrics · 2025Article
- Antiviral Prescription in Children With Influenza in US Emergency Departments: New Vaccine Surveillance Network (NVSN), 2016-2020.Influenza and other respiratory viruses · 2025Article
- Evaluation of a Machine Learning Model Based on Laboratory Parameters for the Prediction of Influenza A and B in Chongqing, China: Multicenter Model Development and Validation Study.Journal of medical Internet research · 2025Article
- Elevated D-dimer on admission may predict poor prognosis in childhood influenza associated encephalopathy.Scientific reports · 2025Article
- Factors Associated With Nonprescription of Oseltamivir for Infant Influenza Over 9 Seasons.Journal of the Pediatric Infectious Diseases Society · 2024Article
- Oseltamivir May or May Not Reduce Hospitalizations.JAMA internal medicine · 2024Article
- Influenza in Children and Adolescents: Epidemiology, Management, and Prevention.Pediatrics in review · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 6 institutions in 1 country.
Funding
Abstract
backgroundNational guidelines recommend antiviral treatment for children with influenza at high risk for complications regardless of symptom duration. Little is known about concordance of clinical practice with this recommendation.
methodsWe performed a cross-sectional study of outpatient children (aged 1-18 years) at high risk for complications who were diagnosed with influenza during the 2016-2019 influenza seasons. High-risk status was determined using an existing definition that includes age, comorbidities, and residence in a long-term care facility. The primary outcome was influenza antiviral dispensing within 2 days of influenza diagnosis. We determined patient- and provider-level factors associated with guideline-concordant treatment using multivariable logistic regression.
resultsOf the 274 213 children with influenza at high risk for influenza complications, 159 350 (58.1%) received antiviral treatment. Antiviral treatment was associated with the presence of asthma (aOR, 1.13; 95% confidence interval [CI], 1.11-1.16), immunosuppression (aOR, 1.10; 95% CI, 1.05-1.16), complex chronic conditions (aOR, 1.04; 95% CI, 1.01-1.07), and index encounter in the urgent care setting (aOR, 1.3; 95% CI, 1.26-1.34). Factors associated with decreased odds of antiviral treatment include age 2-5 years compared with 6-17 years (aOR, 0.95; 95% CI, .93-.97), residing in a chronic care facility (aOR, .61; 95% CI, .46-.81), and index encounter in an emergency department (aOR, 0.66; 95% CI, .63-.71).
conclusionsAmong children with influenza at high risk for complications, 42% did not receive guideline-concordant antiviral treatment. Further study is needed to elucidate barriers to appropriate use of antivirals in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.